Video

CSCC: Translating Cemiplimab Data Into Practice

Author(s):

Nikhil Kushalani, MD,Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute

Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
View More
Related Content
Melanoma | Maris– stock.adobe.com
April 25th 2025

China’s NMPA Approves Toripalimab in First-Line Melanoma

Liliana Bustamante, MD, medical oncologist, hematologist, Florida Cancer Specialists & Research Institute; Jessica Stine, MD, medical director, Gynecologic Oncology, Florida Cancer Specialists & Research Institute
April 10th 2025

Peer Support, Adaptability, and Self-Confidence Are Hallmarks of Successful Oncology Careers: With Liliana Bustamante, MD; and Jessica Stine, MD

Immunotherapy Treatment Options in High-Risk or Locally Advanced/Metastatic Non-melanoma and Melanoma: An Evolving Treatment Landscape
April 17th 2025

Immunotherapy Treatment Options in High-Risk or Locally Advanced/Metastatic Non-melanoma and Melanoma: An Evolving Treatment Landscape

Yvonne Mowery, MD, PhD, physician scientist, associate professor, radiation oncology, University of Pittsburgh Medical Center Hillman Cancer Center
January 7th 2025

Pembrolizumab Plus Preoperative Radiotherapy and Surgery Improves DFS in Soft-Tissue Sarcoma: With Yvonne Mowery, MD, PhD

Uveal Melanoma | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
April 3rd 2025

Neoadjuvant Darovasertib Receives FDA Breakthrough Therapy Designation for Uveal Melanoma

Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.
April 2nd 2025

OncLive’s FDA Approval Report: The Regulatory Rundown for March 2025